✦ LIBER ✦

Survival outcomes in patients with advanced non-small cell lung cancer treated with erlotinib: expanded access programme data from Belgium (the TRUST study)

✍ Scribed by Van Meerbeeck, J.; Galdermans, D.; Bustin, F.; De Vos, L.; Lechat, I.; Abraham, I.

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An expanded access program of erlotinib

✍ Tiseo, Marcello; Gridelli, Cesare; Cascinu, Stefano; Crinò, Lucio; Piantedosi, F 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 541 KB

Outcomes of patients with advanced non-s

✍ Jänne, Pasi A.; Gurubhagavatula, Sarada; Yeap, Beow Y.; Lucca, Joan; Ostler, Pat 📂 Article 📅 2004 🏛 Elsevier Science 🌐 English ⚖ 134 KB

Second-line erlotinib in patients with a

✍ Heigener, David F.; Wu, Yi-Long; van Zandwijk, Nico; Mali, Pekka; Horwood, Keith 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 347 KB

Clinical surrogate markers of survival i

✍ Cedrés, Susana; Prat, Aleix; Martínez, Pablo; Pallisa, Esther; Sala, Gemma; Andr 📂 Article 📅 2009 🏛 Elsevier Science 🌐 English ⚖ 341 KB

A phase II study of enzastaurin in combi

✍ Clément-Duchêne, Christelle; Natale, Ronald B.; Jahan, Thierry; Krupitskaya, Yel 📂 Article 📅 2012 🏛 Elsevier Science 🌐 English ⚖ 300 KB

Efficacy of erlotinib in patients with a

✍ Michael BOYER; Keith HORWOOD; Nick PAVLAKIS; Paul DE SOUZA; Michael MILLWARD; Br 📂 Article 📅 2012 🏛 John Wiley and Sons 🌐 English ⚖ 98 KB